SCHEMBL1011260

SCHEMBL1011260

COC(=O)Cc1cccc(Oc2ccc(C(F)(F)F)cc2CN(C)S(=O)(=O)c2ccc(OC)cc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 2/20 0.46
BMP1 P13497 2/20 0.45
KDM4E B2RXH2 2/20 0.43
MMP9 P14780 4/20 0.43
MMP13 P45452 4/20 0.43
MMP1 P03956 3/20 0.43
MAPT P10636 2/20 0.42
TAS2R14 Q9NYV8 1/20 0.42
LMNA P02545 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
SCN9A Q15858 1/20 0.42
KCNQ3 O43525 1/20 0.42
KCNQ2 O43526 1/20 0.42
ALDH1A1 P00352 1/20 0.41
TBXA2R P21731 1/20 0.41
PTGDR Q13258 1/20 0.41
ADAM17 P78536 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1010903 0.92 PTGDR2 (0.53) PTGDR2BMP1MMP9MMP13MMP1
SCHEMBL1944279 0.91 BMP1 (0.47) PTGDR2BMP1MMP9MMP13MMP1
SCHEMBL1061245 0.86 PTGDR2 (0.42) PTGDR2SCN9AKCNQ3KCNQ2TBXA2R
SCHEMBL1011259 0.84 PTGDR2 (0.45) PTGDR2KDM4EMAPTLMNASMN1; SMN2
SCHEMBL1008968 0.84 PTGDR2 (0.52) PTGDR2TBXA2RPTGDR
SCHEMBL1943761 0.84 PTGDR2 (0.46) PTGDR2MAPTTAS2R14LMNASMN1; SMN2
SCHEMBL1009651 0.84 KCNQ3 (0.46) PTGDR2BMP1MAPTLMNASMN1; SMN2
SCHEMBL1943683 0.83 MAPT (0.44) PTGDR2BMP1MAPTLMNASMN1; SMN2
SCHEMBL13580775 0.83 MAPT (0.42) PTGDR2BMP1MAPTTAS2R14LMNA
SCHEMBL1946754 0.83 PTGDR2 (0.51) PTGDR2BMP1TAS2R14SCN9ATBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426449-B2 Aminoalkylphenyl antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2013-04-23 US disclosed
US-8426449-B2 Aminoalkylphenyl antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2013-04-23 US disclosed
US-8426449-B2 Aminoalkylphenyl antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2013-04-23 US disclosed
US-20110130453-A1 AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2011-06-02 US disclosed
US-20110130453-A1 AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2011-06-02 US disclosed
US-20110130453-A1 AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2011-06-02 US disclosed
EP-2268611-A2 AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS Amira Pharmaceuticals, Inc. (US) 2011-01-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130453-A1 AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PTGDR, PTGDR2, PTGER2 PTGDR2 2/4885BMP1 3268/4885KDM4E 4753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.